Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02764346
Other study ID # 1000049274
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date December 2019

Study information

Verified date April 2020
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will look at the use and impact of smartphone application (app) for adolescents with ongoing pain caused by their juvenile idiopathic arthritis (JIA).The current project will include three studies. First, the investigators conducted usability sessions with adolescents with JIA to refine the app so that it is usable, acceptable and understandable. The aim of this study is to look at (a) how regularly the "iCanCope with Pain" app is used and (b) any effect the app has on young people's health. This study will compare two groups of young people: one that is using the new app, and one that receives usual medical care.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria

1. Aged 12-18 years

2. Diagnosed with JIA (36) as per their rheumatologist

3. Able to speak and read English

4. Have self-reported average arthritis-related pain in the past week of >3 on 10cm visual analogue scale (VAS)

5. Willing to complete online study outcome measures

Exclusion Criteria:

1. Moderate to severe cognitive impairments as per their healthcare provider

2. Major co-morbid psychiatric [conversion disorder, depression, anxiety disorder] illnesses that may impact their ability to understand and use the "iCanCope with Pain" intervention as per their rheumatologist

3. Received more than 4 CBT sessions for pain management in the past 6 months, as per their healthcare provider and self-report

4. Patients from the department of haematology/oncology

Study Design


Intervention

Behavioral:
iCanCope app
In addition to standard medical care, adolescents in the experimental group will receive access to the "iCanCope" smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component.
iCanCope attention control app
The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the "iCanCope" control app, with limited functionality.

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
The Hospital for Sick Children Alberta Children's Hospital, British Columbia Children's Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participant accrual rate Centrally tracked by the clinical research project coordinator 8 weeks
Primary Number of issues or difficulties in implementing the intervention The intervention fidelity log will track any issues or difficulties encountered during implementation of the intervention, control strategy, or outcome measures will be tracked throughout the study by the CRPC. 8 weeks
Primary Acceptability of intervention Participants in the intervention arm will complete the Acceptability e-scale (AES) post-intervention. In addition, a subset of participants from the intervention group will be offered to participate in a qualitative feedback interview to further explore acceptability of the intervention. 8 weeks
Primary Frequency of login per user Measured through the iCanCope server. 8 weeks
Primary Adherence Adherence will be determined using Google Analytics. 8 weeks
Primary Adverse Events Adverse events will be tracked using an adverse event form 8 weeks
Primary Participant dropout rate Centrally tracked by clinical research project coordinator 8 weeks
Primary Satisfaction of intervention A subset of participants from the intervention group will be offered to participate in a qualitative feedback interview to further explore satisfaction of the intervention. 8 weeks
Secondary Pain Pain will be measured using the Standardized Universal Pain Evaluations for Rheumatology providers for children and youth (SUPERKIDZ). It consists of 4 domains: pain intensity and location (5 items), fatigue (1 item), pain interference/evaluative dimension (10 items), and affective/emotional dimension (4 items) for children > 8 years. This online measure takes 3 - 5 minutes to complete, and has evidence of test-retest reliability, construct validity, and responsiveness. 8 weeks
Secondary Pain-Related Activity Limitations Pain-related activity limitations will be measured using the Child Activity Limitations Interview (CALI-21). This is a well-validated 21-item self-report scale divided into (i) active (e.g., gym, sports) and (ii) routine (e.g., schoolwork, reading) activity subscales. 8 weeks
Secondary Pain coping Pain coping will be measured using the Pain Coping Questionnaire which is an internationally used measure of pain coping strategies in pediatric populations. Respondents indicate on a 5-point scale how often they use a given type of coping strategy from among 8 different categories. Three higher order factor-derived subscale scores will be used for analyses, including approach coping (e.g., problem-solving), problem-focused avoidance coping (e.g., cognitive distraction), and emotion-focused avoidance coping (e.g., catastrophizing). The measure is considered to meet psychometric criteria for a "well-established" coping measure and is responsive to pain coping interventions. 8 weeks
Secondary Health-Related Quality of Life (HRQoL) HRQoL will be measured using the PedsQL 3.0 Arthritis Module, which measures the potential impact on quality of life of having arthritis in childhood. The scale has 22 items and evaluates the severity of perceived problems with disease symptoms, daily activity limitations, treatments, worry/anxiety, and communication. 8 weeks
Secondary Health care utilization form This will be used to measure direct health care costs and patient/family out of pocket costs related to arthritis care 8 weeks
Secondary Health Utility Index Used to calculate quality adjusted life years (QALYs) 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02776735 - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Phase 2
Active, not recruiting NCT03092427 - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) N/A
Not yet recruiting NCT05545098 - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting NCT03833609 - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis N/A
Completed NCT02524340 - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting NCT01434082 - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis N/A
Completed NCT04671524 - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected N/A
Recruiting NCT04167488 - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy N/A
Recruiting NCT04205500 - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis N/A
Terminated NCT01694264 - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Phase 3
Completed NCT02824978 - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Phase 3
Completed NCT03833271 - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary Early Phase 1
Completed NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 1
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT01436019 - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis N/A
Recruiting NCT05609630 - Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Phase 3
Recruiting NCT05696340 - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05436301 - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)